Virax Biolabs Group Ltd (VRAX): רווח נקי למניה (EPS TTM)

Virax Biolabs Group (VRAX) is recruiting leading immunologists to develop IT systems for viral profiling, enabling the expansion of a global network for diagnostics and digital health passports. Net earnings per share over the last four quarters illustrate this progress, with the -17.01 metric serving as the target level. Growth potential remains strong due to the deployment of mobile diagnostic platforms within the undersaturated market for rare pathologies.
פילוחי מדדים ואנליטיקה של חברת Virax Biolabs Corp (VRAX)

Fundamental asset screening requires precise measurement of capital efficiency. This indicator calculates the specific share of net income per share annually, neutralizing the impact of issuance. By analyzing the rolling annual earnings per share of Virax Biolabs Group (VRAX), an investor can discern the real business yield without market noise. The stability of this metric confirms the sustainable position of Virax Biolabs Group (VRAX) as a trusted supplier of diagnostic systems. A high level of market recognition ensures predictable profit generation.